# Safety and Tolerability of PRO-185

> **NCT05470868** · PHASE1 · COMPLETED · sponsor: **Laboratorios Sophia S.A de C.V.** · enrollment: 22 (actual)

## Conditions studied

- Hyperemia Eye

## Interventions

- **DRUG:** Naphazoline / Hypromellose Ophthalmic

## Key facts

- **NCT ID:** NCT05470868
- **Lead sponsor:** Laboratorios Sophia S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-04
- **Primary completion:** 2023-05-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05470868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05470868, "Safety and Tolerability of PRO-185". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05470868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*